|
related topics |
{product, liability, claim} |
{property, intellectual, protect} |
{personnel, key, retain} |
{condition, economic, financial} |
{debt, indebtedness, cash} |
{cost, operation, labor} |
{customer, product, revenue} |
{cost, contract, operation} |
{stock, price, share} |
|
Our lack of earnings history could adversely affect our financial health and prevent us from fulfilling our payment obligations, and if we are unable to generate funds or obtain funds on acceptable terms, we may not be able to develop and market our present and potential products.
Our debt instruments contain restrictive covenants that could adversely affect our business by limiting our flexibility.
We may fail to realize the anticipated cost savings, revenue enhancements, product focus, or other benefits expected from our recent acquisition of Pro-Dentec.
Historically we have been dependent on a few key products and our future growth is dependent on the development and/or acquisition of new products.
Our proprietary rights may prove difficult to enforce.
We are dependent on our senior management and other key personnel.
We and our products are subject to regulatory oversight that could substantially interfere with our ability to do business.
We are at risk with respect to product liability claims.
We face significant competition that could adversely affect our results of operation and financial condition.
If the use of our technology is determined to infringe on the intellectual property rights of others, our business could be harmed.
We require certain raw materials for our manufacturing processes that may only be acquired through limited sources.
We have, in the past, received minor deficiencies from regulatory agencies related to our manufacturing facilities.
Trends, Risks and Uncertainties Related to Our Capital Stock
The Private Placements and other financing arrangements or corporate events could significantly dilute existing ownership.
Full 10-K form ▸
|
|
related documents |
827156--10/6/2008--ZILA_INC |
827156--10/10/2006--ZILA_INC |
31791--2/28/2008--PERKINELMER_INC |
739944--3/15/2007--MEDTOX_SCIENTIFIC_INC |
768408--6/24/2010--CYANOTECH_CORP |
739944--3/11/2008--MEDTOX_SCIENTIFIC_INC |
739944--3/10/2009--MEDTOX_SCIENTIFIC_INC |
739944--3/17/2006--MEDTOX_SCIENTIFIC_INC |
1114200--2/27/2008--AMERICAN_MEDICAL_SYSTEMS_HOLDINGS_INC |
780127--1/12/2007--SYNOVIS_LIFE_TECHNOLOGIES__INC |
911649--4/2/2007--STRATEGIC_DIAGNOSTICS_INC/DE/ |
862668--9/29/2008--ESCALON_MEDICAL_CORP |
10456--2/26/2008--BAXTER_INTERNATIONAL_INC |
880432--9/28/2009--MISONIX_INC |
1050007--11/30/2006--NUTRACEUTICAL_INTERNATIONAL_CORP |
31791--2/26/2009--PERKINELMER_INC |
1033905--3/16/2006--LUMINEX_CORP |
912093--8/31/2010--JDS_UNIPHASE_CORP_/CA/ |
882873--9/21/2009--UROLOGIX_INC |
1263074--3/14/2008--PORTEC_RAIL_PRODUCTS_INC |
862668--10/12/2010--ESCALON_MEDICAL_CORP |
1006195--3/15/2007--MATRIXX_INITIATIVES_INC |
810084--4/2/2007--BIOJECT_MEDICAL_TECHNOLOGIES_INC |
7536--2/8/2008--ARROW_ELECTRONICS_INC |
874734--3/8/2010--OSTEOTECH_INC |
874734--3/16/2009--OSTEOTECH_INC |
874710--9/26/2008--ALLIED_HEALTHCARE_PRODUCTS_INC |
874710--9/28/2007--ALLIED_HEALTHCARE_PRODUCTS_INC |
31791--3/1/2010--PERKINELMER_INC |
1005010--2/29/2008--ARTHROCARE_CORP |
|